N/A
Completed N=27
Tissue Penetration of Antibiotics in Obesity
Source: ClinicalTrials.gov NCT00752908 ↗Enrolled (actual)
27
Serious AEs
0.0%
Results posted
Sep 2019
Primary outcomePrimary: Cefoxitin Plasma Concentrations — 89; 81 (µg/mL) — p=<0.05
Summary
The purpose of this study is to evaluate cefoxitin pharmacokinetics in obese surgical patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cefoxitin Plasma Concentrations |
89; 81 | <0.05 sig |
| SECONDARY Cefoxitin Tissue Concentrations |
8.8; 26 | — |
Eligibility Criteria
Inclusion Criteria
- BMI 40
- Scheduled for elective abdominal or pelvic surgery
- Surgical plan for intraoperative cefoxitin prophylaxis
- Able to provide informed consent
Exclusion Criteria
- Allergy to Cefoxitin
- Renal or Hepatic insufficiency
Data sourced from ClinicalTrials.gov (NCT00752908). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.